Anticancer therapy in patients with porphyrias: evidence today.
Fiche publication
Date publication
mars 2008
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Pr PIVOT Xavier, Dr THIERY-VUILLEMIN Antoine, Dr DEMARCHI Martin
Tous les auteurs :
Thiery-Vuillemin A, Chaigneau L, Meaux-Ruault N, Villanueva C, N'guyen T, Maurina T, Stein U, Lorgis V, Demarchi M, Pivot X
Lien Pubmed
Résumé
BACKGROUND: Porphyrias are rare diseases, and for these patients every administration of drugs may induce an acute attack of porphyria. The list of safe compounds allowed in these patients is available for clinicians from specific websites cited in the text. OBJECTIVES: However, data concerning anticancer therapy in patients with such diseases remain poor. Therefore any publications can help clinicians to deal with this very specific group of patients. METHODS: In our institution, three patients received docetaxel and hematologic growth factors (erythropoietin and GCSF) without unexpected toxicities. Aromatase inhibitors (anstrozole and letrozole) were also given in one patient without any related problem. CONCLUSION: The present observation adds some useful data for the possible treatment of cancer in patients with porphyria.
Référence
Expert Opin Drug Saf. 2008 Mar;7(2):159-65.